Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aritinercept · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Aritinercept | EXPERIMENTAL | Double-Blind Treatment Period: Aritinercept by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Double-Blind Treatment Period: Placebo by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Aritinercept | DRUG | For subcutaneous injection |
| Placebo | OTHER | For subcutaneous injection |
Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeed...
Aritinercept is an investigational small molecule being developed for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Aritinercept targets BAFF/APRIL, which are cytokines involved in B-cell survival and antibody production. By modulating this pathway, the drug aims to address the autoimmune processes underlying generalized myasthenia gravis.
Aritinercept is being developed by Aurinia Pharmaceuticals Inc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol AUPH. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
Aritinercept is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to assess its safety and effectiveness in patients.
Aritinercept is being studied in a Phase 1 clinical trial with the identifier NCT07596901. This randomized, double-blind, placebo-controlled study is recruiting 81 participants with generalized myasthenia gravis in the United States.
No alternative names for Aritinercept have been reported. It is identified solely by its generic name and is being investigated under the clinical trial NCT07596901 for generalized myasthenia gravis.